Investors, CBD Pharma Co. Reach Deal Over Clinical Trial Suit
Stockholders pressing consolidated, derivative damage claims against CBD drugmaker Zynerba Pharmaceuticals sought preliminary approval Friday for settlement of a federal suit in Delaware targeting damage to the company from undisclosed adverse...To view the full article, register now.
Already a subscriber? Click here to view full article